Approved combinations with anti-PD-1/PD-L1 (e.g. Atezolizumab + Bevacizumab in HCC, Pembrolizumab + Axitinib in RCC). Clinical efficacy validated. This evidence concerns the gene CD274 and renal cell carcinoma.